STATERA BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0006 USD | -.--% |
|
-14.29% | -99.98% |
| 2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
| 2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
Presenter SpeechC. Lyons (Executives)Good morning, ladies and gentlemen, and welcome to the 20...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the bodyâs immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohnâs disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.
| 1st Jan change | Capi. | |
|---|---|---|
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- STAB Stock
- STAB Stock
- News Statera Biopharma, Inc.
- Transcript : Cleveland BioLabs, Inc. - Shareholder/Analyst Call
